http://www.efsa.europa.eu/
EFSA’s NDA Panel[1] has published the outcome of the evaluations of a fourth series of ‘general function’ health claims[2] proposed for use on food products. The 442 claims assessed relate to health relationships in such areas as: protection against oxidative damage to body cells, contribution to either cognitive or bowel function; and maintenance of normal blood cholesterol levels. These opinions will help inform future decisions of the European Commission and EU Member States which are responsible for the authorisation of the claims. EFSA will finalise the evaluation of the remaining 600 ‘general function’ health claims which need to be assessed by June 2011.